99329-52-9

Basic information

• Product Name: Benzeneacetonitrile, a-(3-bromopropyl)-3,4-dimethoxy-a-(1-methylethyl)-
• CAS NO: 99329-52-9
• Molecular Formula: C16H22BrNO2
• Molecular Weight: 340.26
• Mol File: 99329-52-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzeneacetonitrile, a-(3-bromopropyl)-3,4-dimethoxy-a-(1-methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetonitrile, a-(3-bromopropyl)-3,4-dimethoxy-a-(1-methylethyl)-(99329-52-9)
• EPA Substance Registry System: Benzeneacetonitrile, a-(3-bromopropyl)-3,4-dimethoxy-a-(1-methylethyl)-(99329-52-9)

Safety Data

• Hazardous Substances Data: 99329-52-9(Hazardous Substances Data)

Upstream product

• 20850-49-1 2-(3,4-dimethoxyphenyl)-3-methylbutyronitrile 
• 109-64-8 1,3-dibromo-propane 
• 93-17-4 3,4-dimethoxyphenylacetonitrile 

Downstream Products

• 229624-48-0 N-<4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl>phthalimide 
• 808749-02-2 5-(1-benzylpiperidin-4-ylamino)-2-(3,4-dimethoxyphenyl)-2-(methylethyl)pentanenitrile 

Relevant articles and documents

HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: Discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range

On the basis of the results obtained in previous research, three series of compounds (A-C), derived from verapamil, were designed and synthesized to obtain drugs able to revert multidrug resistance (MDR), an acquired resistance that frequently impairs cancer chemotherapy. The ability of the obtained compounds to revert MDR was evaluated on anthracycline-resistant erythroleukemia K 562 cells, measuring the uptake of THP-adriamycin (pirarubicin) by continuous spectrofluorometric monitoring of the decrease of the fluorescence signal of the anthracycline at 590 nm (λ(ex) = 480 nm), after incubation with cells. Cardiovascular activity, which is responsible for unwanted side effects, was also evaluated. The results obtained show that many of the compounds studied are potent reverters of MDR and are endowed with reduced cardiovascular activity. One of the compounds (7, MM36) presents a pharmacological profile (unprecedented nanomolar potency, high reversal of MDR, low cardiovascular activity) that makes it a promising drug candidate to treat MDR and a useful tool for studying P-glycoprotein.